PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:PBH - US74112D1019 - Common Stock
60.82 USD
+0.76 (+1.27%)
60.82 USD
0 (0%)
Taking everything into account, PBH scores 6 out of 10 in our fundamental rating. PBH was compared to 192 industry peers in the Pharmaceuticals industry. PBH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PBH is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
PBH had positive earnings in the past year.
PBH had a positive operating cash flow in the past year.
PBH had positive earnings in 4 of the past 5 years.
Each year in the past 5 years PBH had a positive operating cash flow.
1.2 Ratios
PBH has a better Return On Assets (5.83%) than 86.98% of its industry peers.
The Return On Equity of PBH (11.00%) is better than 85.94% of its industry peers.
Looking at the Return On Invested Capital, with a value of 7.88%, PBH belongs to the top of the industry, outperforming 85.94% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for PBH is below the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROIC | 7.88% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
The Profit Margin of PBH (18.09%) is better than 90.10% of its industry peers.
In the last couple of years the Profit Margin of PBH has grown nicely.
The Operating Margin of PBH (31.00%) is better than 94.27% of its industry peers.
In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
With a decent Gross Margin value of 56.10%, PBH is doing good in the industry, outperforming 67.71% of the companies in the same industry.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PBH is destroying value.
PBH has less shares outstanding than it did 1 year ago.
The number of shares outstanding for PBH has been reduced compared to 5 years ago.
Compared to 1 year ago, PBH has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.53 indicates that PBH is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.53, PBH is in the better half of the industry, outperforming 65.10% of the companies in the same industry.
The Debt to FCF ratio of PBH is 3.97, which is a good value as it means it would take PBH, 3.97 years of fcf income to pay off all of its debts.
PBH's Debt to FCF ratio of 3.97 is amongst the best of the industry. PBH outperforms 85.94% of its industry peers.
PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
PBH's Debt to Equity ratio of 0.55 is on the low side compared to the rest of the industry. PBH is outperformed by 65.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 2.53 |
ROIC/WACC0.91
WACC8.61%
2.3 Liquidity
A Current Ratio of 3.70 indicates that PBH has no problem at all paying its short term obligations.
PBH has a Current ratio (3.70) which is comparable to the rest of the industry.
A Quick Ratio of 2.51 indicates that PBH has no problem at all paying its short term obligations.
The Quick ratio of PBH (2.51) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.15%, which is quite good.
The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
PBH shows a decrease in Revenue. In the last year, the revenue decreased by -0.02%.
The Revenue has been growing slightly by 3.39% on average over the past years.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
PBH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.13% yearly.
The Revenue is expected to grow by 1.15% on average over the next years.
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 13.34 indicates a correct valuation of PBH.
PBH's Price/Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 87.50% of the companies in the same industry.
PBH is valuated rather cheaply when we compare the Price/Earnings ratio to 26.46, which is the current average of the S&P500 Index.
PBH is valuated correctly with a Price/Forward Earnings ratio of 12.42.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 84.38% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of PBH to the average of the S&P500 Index (36.10), we can say PBH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.34 | ||
| Fwd PE | 12.42 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaper than 87.50% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PBH is valued cheaper than 88.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.45 | ||
| EV/EBITDA | 10.22 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)8.13
PEG (5Y)1.5
EPS Next 2Y3.96%
EPS Next 3Y3.41%
5. Dividend
5.1 Amount
No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
60.82
+0.76 (+1.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners108.93%
Inst Owner Change-0.57%
Ins Owners1.31%
Ins Owner Change0.82%
Market Cap2.92B
Revenue(TTM)1.11B
Net Income(TTM)200.84M
Analysts84
Price Target79.05 (29.97%)
Short Float %3.32%
Short Ratio3.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)-4.08%
PT rev (3m)-7.3%
EPS NQ rev (1m)-8.06%
EPS NQ rev (3m)-9.11%
EPS NY rev (1m)0.96%
EPS NY rev (3m)0.71%
Revenue NQ rev (1m)-2.41%
Revenue NQ rev (3m)-5.22%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)0.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.34 | ||
| Fwd PE | 12.42 | ||
| P/S | 2.63 | ||
| P/FCF | 11.45 | ||
| P/OCF | 11.1 | ||
| P/B | 1.6 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.22 |
EPS(TTM)4.56
EY7.5%
EPS(NY)4.9
Fwd EY8.05%
FCF(TTM)5.31
FCFY8.74%
OCF(TTM)5.48
OCFY9.01%
SpS23.1
BVpS37.96
TBVpS-20.68
PEG (NY)8.13
PEG (5Y)1.5
Graham Number62.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROCE | 10.41% | ||
| ROIC | 7.88% | ||
| ROICexc | 8.17% | ||
| ROICexgc | 70.59% | ||
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% | ||
| FCFM | 23% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 27.11% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.8 | ||
| Cash Conversion | 70.49% | ||
| Profit Quality | 127.19% | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | 2.53 |
F-Score7
WACC8.61%
ROIC/WACC0.91
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year6.22%
EBIT Next 3Y3.43%
EBIT Next 5Y3.05%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
What is the valuation status for PBH stock?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
How profitable is PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
How financially healthy is PRESTIGE CONSUMER HEALTHCARE?
The financial health rating of PRESTIGE CONSUMER HEALTHCARE (PBH) is 7 / 10.
What is the earnings growth outlook for PRESTIGE CONSUMER HEALTHCARE?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.64% in the next year.